Health Care & Life Sciences » Pharmaceuticals | Sanochemia Pharmazeutika AG

Sanochemia Pharmazeutika AG | Income Statement

Fiscal year is October-September. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
33,302.00
34,051.00
35,620.00
39,301.00
41,363.00
33,026
Cost of Goods Sold (COGS) incl. D&A
26,437.00
29,873.00
27,022.00
31,029.00
32,422.00
28,706
Gross Income
6,865.00
4,178.00
8,598.00
8,272.00
8,941.00
4,320
SG&A Expense
5,156.00
4,711.00
5,620.00
8,643.00
8,613.00
12,421
EBIT
2,356.00
326.00
3,077.00
272.00
328.00
8,027
Non Operating Income/Expense
2,582.00
1,902.00
1,431.00
894.00
875.00
415
Interest Expense
992.00
1,173.00
1,126.00
1,123.00
1,458.00
719
Pretax Income
710.00
3,312.00
570.00
458.00
210.00
13,413
Income Tax
515.00
83.00
186.00
97.00
42.00
136
Consolidated Net Income
1,225.00
3,395.00
384.00
555.00
252.00
13,277
Net Income
1,225.00
3,395.00
384.00
555.00
252.00
13,277
Net Income After Extraordinaries
1,225.00
3,395.00
384.00
555.00
252.00
13,277
Net Income Available to Common
1,225.00
3,395.00
384.00
555.00
252.00
13,277
EPS (Basic)
0.10
0.26
0.03
0.04
0.02
1.03
Basic Shares Outstanding
12,872.10
12,872.10
12,872.10
12,872.10
12,872.10
12,872.10
EPS (Diluted)
0.10
0.26
0.03
0.04
0.02
1.03
Diluted Shares Outstanding
12,872.10
12,872.10
12,872.10
12,872.10
12,872.10
12,872.10
EBITDA
845.00
2,813.00
5,634.00
2,242.00
2,749.00
5,724
Other Operating Expense
4,065.00
207.00
99.00
99.00
-
74
Non-Operating Interest Income
56.00
89.00
50.00
43.00
45.00
34

About Sanochemia Pharmazeutika

View Profile
Address
Boltzmanngasse 11
Vienna Wien (Vienna) 1090
Austria
Employees -
Website http://www.sanochemia.at
Updated 07/08/2019
SANOCHEMIA Pharmazeutika AG engages in the manufacture and distribution of pharmaceutical products. It operates through the following segments: Production, Human Pharmaceuticals, Veterinary Pharmaceuticals, and Research and Development. The Production segment focuses on synthesis of active pharmaceutical substances, drug formulation and pharmaceutical production.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.